7 hours ago
5
ARTICLE AD BOX
Jubilant Pharmova's sterile CMO and allergy Immunotherapy posts strong growth in Q2.
03 Nov 2025, 10:13 AM IST i 03 Nov 2025, 10:13 AM IST 03 Nov 2025, 10:13 AM IST
Jubilant Pharmova's Q2 FY26 revenue of Rs 19,664 million was up 12.2% YoY and 3.5% QoQ. (Photo: Mika Baumeister/Unsplash)
While the revenue across all businesses was broadly in line, Allergy Immunotherapy and CMO – Sterile Injectables business outperformed expectations.
To continue reading this story
You must be an existing Premium User
Already a Premium User?
English (US) ·